The role of genetics in pre-eclampsia and potential pharmacogenomic interventions

Pharmacogenomics and Personalized Medicine

Volumn 5, Issue 1, 2012, Pages 37-51

  Williams, Paula Juliet ^a   Morgan, Linda ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Genetics; Pharmacogenetics; Placenta; Pre eclampsia; Trophoblast

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CATECHOL METHYLTRANSFERASE; DIURETIC AGENT; HLA ANTIGEN; HYDRALAZINE; INTERLEUKIN 10; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LABETALOL; MAGNESIUM SULFATE; NICARDIPINE; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PRAVASTATIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASODILATOR AGENT; VERAPAMIL;

ACTIVIN A RECEPTOR TYPE IIA GENE; CYTOKINE RELEASE; DRUG METABOLISM; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOGENETICS; LIPID METABOLISM; LOW DRUG DOSE; MOLECULAR GENETICS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PLACENTA INSUFFICIENCY; POSTPARTUM HEMORRHAGE; PREECLAMPSIA; PROTEINURIA; REVIEW; RISK FACTOR; ROCK2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOPHILIA; THROMBOSIS; TROPHOBLAST;

EID: 84856810559     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S23141     Document Type: Review

References (142)

1. Redman CW. Preeclampsia: a multi-stress disorder. Rev Med Interne. 2011;32 Suppl 1:S41-S44.
2. Villar K, Say L, Gulmezoglu AM, et al. Eclampsia and pre-eclampsia: a health problem for 2,000 years. In: Critchley H, MacLean AB, Poston L, Walker JJ, editors. Preeclampsia. London: RCOG Press; 2003:189-207.
3. Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ. Pre- eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. Stroke. 2009;40(4):1176-1180.
4. Bauer ST, Cleary KL. Cardiopulmonary complications of pre-eclampsia. Semin Perinatol. 2009;33(3):158-165.
5. Zeeman GG. Neurologic complications of pre-eclampsia. Semin Perinatol. 2009;33(3):166-172.
6. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009;30 Suppl A:S32-S37.
7. Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta. 2009;30 Suppl A:S38-S42.
8. Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63(6):534-543.
9. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20(1):IX-XIV.
10. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 1993;341(8858):1447-1451.
11. McCarthy AL, Taylor P, Graves J, Raju SK, Poston L. Endotheliumdependent relaxation of human resistance arteries in pregnancy. Am J Obstet Gynecol. 1994;171(5):1309-1315.
12. Ward K, Lindheimer MD. Genetic factors in the etiology of preeclampsia/ eclampsia. In: Lindheimer MD, Roberts JM, Cunningham FD, editors. Chesley's Hypertensive Disorders in Pregnancy. London: Elsevier; 2009:51-72.
13. Cox B, Sharma P, Evangelou AI, et al. Translational analysis of mouse and human placental protein and mRNA reveals distinct molecular pathologies in human preeclampsia. Mol Cell Proteomics. 2011;10(12): M111.012526.
14. Vianna P, Bauer ME, Dornfeld D, Chies JA. Distress conditions during pregnancy may lead to pre-eclampsia by increasing cortisol levels and altering lymphocyte sensitivity to glucocorticoids. Med Hypotheses. 2011;77(2):188-191.
15. Robinson CJ, Alanis MC, Wagner CL, Hollis BW, Johnson DD. Plasma 25-hydroxyvitamin D levels in early-onset severe preeclampsia. Am J Obstet Gynecol. 2010;203(4):366.
16. Cooper DW, Brennecke SP, Wilton AN. Genetics of pre-eclampsia. Hypertens Pregnancy. 1993;12:1-23.
17. Fisher SJ, McMaster M, Roberts JM. The placenta in normal pregancy and preeclampsia. In: Lindheimer MD, Roberts JM, Cunningham FD, editors. Chesley's Hypertensive Disorders in Pregnancy. London: Elsevier; 2009:73-86.
18. Kurdoglu M, Kurdoglu Z, Ozen S, et al. Expression of laminin receptor 1 in human placentas from normal and preeclamptic pregnancies and its relationship with the severity of preeclampsia. J Perinat Med. 2011;39(4):411-416.
19. Skjaerven R, Vatten LJ, Wilcox AJ, Ronning T, Irgens LM, Lie RT. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ. 2005;331(7521):877.
20. Haig D. Genetic conflicts in human pregnancy. Q Rev Biol. 1993;68(4): 495-532.
21. GOPEC Consortium. Disentangling fetal and maternal susceptibility for pre-eclamspia: a British multicenter candidate-gene study. Am J Hum Genet. 2005;77:127-131.
22. Dekker G, Robillard PY, Roberts C. The etiology of preeclampsia: the role of the father. J Reprod Immunol. 2011;89(2):126-132.
23. Ainsworth HF, Unwin J, Jamison DL, Cordell HJ. Investigation of maternal effects, maternal-fetal interactions and parent-of-origin effects (imprinting), using mothers and their offspring. Genet Epidemiol. 2011;35(1):19-45.
24. Mutze S, Rudnik-Schoneborn S, Zerres K, Rath W. Genes and the preeclampsia syndrome. J Perinat Med. 2008;36(1):38-58.
25. de Maat MP, de Groot CJ. Thrombophilia and pre-eclampsia. Semin Thromb Hemost. 2011;37(2):106-110.
26. Isermann B, Sood R, Pawlinski R, et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med. 2003; 9(3):331-337.
27. Dalmaz CA, Santos KG, Botton MR, Tedoldi CL, Roisenberg I. Relationship between polymorphisms in thrombophilic genes and preeclampsia in a Brazilian population. Blood Cells Mol Dis. 2006;37(2): 107-110.
28. Gerhardt A, Goecke TW, Beckmann MW, et al. The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia. J Thromb Haemost. 2005;3(4):686-691.
29. Lin J, August P. Genetic thrombophilias and preeclampsia: a metaanalysis. Obstet Gynecol. 2005;105(1):182-192.
30. Rodger MA, Betancourt MT, Clark P, et al. The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med. 2010;7(6):e1000292.
31. Medica I, Kastrin A, Peterlin B. Genetic polymorphisms in vasoactive genes and preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2007;131(2):115-126.
32. Zafarmand MH, Nijdam ME, Franx A, Grobbee DE, Bots ML. The angiotensinogen gene M235T polymorphism and development of preeclampsia/eclampsia: a meta-analysis and meta-regression of observational studies. J Hypertens. 2008;26(9):1726-1734.
33. Brennecke SP, Gude NM, Di Iulio JL, King RG. Reduction of placental nitric oxide synthase activity in pre-eclampsia. Clin Sci (Lond). 1997;93(1):51-55.
34. Papazoglou D, Galazios G, Koukourakis MI, et al. Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod. 2004;10(5):321-324.
35. Bower C, Stanley F, Walters BN. Pre-eclampsia and trisomy 13. Lancet. 1987;2(8566):1032.
36. Chen CP. Placental abnormalities and preeclampsia in trisomy 13 pregnancies. Taiwan J Obstet Gynecol. 2009;48(1):3-8.
37. Burton GJ, Jauniaux E. Oxidative stress. Best Pract Res Clin Obstet Gynaecol. 2011;25(3):287-299.
38. Jauniaux E, Poston L, Burton GJ. Placental-related diseases of pregnancy: Involvement of oxidative stress and implications in human evolution. Hum Reprod Update. 2006;12(6):747-755.
39. Foidart JM, Hustin J, Dubois M, Schaaps JP. The human placenta becomes haemochorial at the 13th week of pregnancy. Int J Dev Biol. 1992;36(3):451-453.
40. Walker JJ. Antioxidants and inflammatory cell response in preeclampsia. Semin Reprod Endocrinol. 1998;16(1):47-55.
41. Mistry HD, Kurlak LO, Williams PJ, Ramsay MM, Symonds ME, Pipkin FB. Differential expression and distribution of placental glutathione peroxidases 1, 3 and 4 in normal and preeclamptic pregnancy. Placenta. 2010;31(5):401-408.
42. Wickens D, Wilkins MH, Lunec J, Ball G, Dormandy TL. Free radical oxidation (peroxidation) products in plasma in normal and abnormal pregnancy. Ann Clin Biochem. 1981;18(Pt 3):158-162.
43. Canto P, Canto-Cetina T, Juarez-Velazquez R, et al. Methylenetetrahydrofolate reductase C677T and glutathione S-transferase P1 A313G are associated with a reduced risk of preeclampsia in Maya-Mestizo women. Hypertens Res. 2008;31(5):1015-1019.
44. Gebhardt GS, Peters WH, Hillermann R, et al. Maternal and fetal single nucleotide polymorphisms in the epoxide hydrolase and gluthatione S-transferase P1 genes are not associated with pre-eclampsia in the Coloured population of the Western Cape, South Africa. J Obstet Gynaecol. 2004;24(8):866-872.
45. Laasanen J, Romppanen EL, Hiltunen M, et al. Two exonic single nucleotide polymorphisms in the microsomal epoxide hydrolase gene are jointly associated with preeclampsia. Eur J Hum Genet. 2002;10(9):569-573.
46. Descamps OS, Bruniaux M, Guilmot PF, Tonglet R, Heller FR. Lipoprotein metabolism of pregnant women is associated with both their genetic polymorphisms and those of their newborn children. J Lipid Res. 2005;46(11):2405-2414.
47. Kim YJ, Williamson RA, Chen K, Smith JL, Murray JC, Merrill DC. Lipoprotein lipase gene mutations and the genetic susceptibility of preeclampsia. Hypertension. 2001;38(5):992-996.
48. Atkinson KR, Blumenstein M, Black MA, et al. An altered pattern of circulating apolipoprotein E3 isoforms is implicated in preeclampsia. J Lipid Res. 2009;50(1):71-80.
49. Zhang C, Austin MA, Edwards KL, et al. Functional variants of the lipoprotein lipase gene and the risk of preeclampsia among non- Hispanic Caucasian women. Clin Genet. 2006;69(1):33-39.
50. Wang JX, Knottnerus AM, Schuit G, Norman RJ, Chan A, Dekker GA. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet. 2002;359(9307):673-674.
51. Klatsky PC, Delaney SS, Caughey AB, Tran ND, Schattman GL, Rosenwaks Z. The role of embryonic origin in preeclampsia: a comparison of autologous in vitro fertilization and ovum donor pregnancies. Obstet Gynecol. 2010;116(6):1387-1392.
52. Bulmer JN, Williams PJ, Lash GE. Immune cells in the placental bed. Int J Dev Biol. 2010;54(2-3):281-294.
53. Hiby SE, Walker JJ, O'Shaughnessy KM, et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med. 2004;200(8):957-965.
54. Sharma A, Satyam A, Sharma JB. Leptin, IL-10 and inflammatory markers (TNF-alpha, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women. Am J Reprod Immunol. 2007;58(1):21-30.
55. Alexander BT, Cockrell KL, Massey MB, Bennett WA, Granger JP. Tumor necrosis factor-alpha-induced hypertension in pregnant rats results in decreased renal neuronal nitric oxide synthase expression. Am J Hypertens. 2002;15(2 Pt 1):170-175.
56. Elahi MM, Asotra K, Matata BM, Mastana SS. Tumor necrosis factor alpha -308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta. 2009;1792(3): 163-172.
57. Saarela T, Hiltunen M, Helisalmi S, Heinonen S, Laakso M. Tumour necrosis factor-alpha gene haplotype is associated with pre-eclampsia. Mol Hum Reprod. 2005;11(6):437-440.
58. Bombell S, McGuire W. Tumour necrosis factor (-308A) polymorphism in pre-eclampsia: meta-analysis of 16 case-control studies. Aust N Z J Obstet Gynaecol. 2008;48(6):547-551.
59. Renaud SJ, Macdonald-Goodfellow SK, Graham CH. Coordinated regulation of human trophoblast invasiveness by macrophages and interleukin 10. Biol Reprod. 2007;76(3):448-454.
60. Makris A, Xu B, Yu B, Thornton C, Hennessy A. Placental deficiency of interleukin-10 (IL-10) in preeclampsia and its relationship to an IL10 promoter polymorphism. Placenta. 2006;27(4-5):445-451.
61. Daher S, Sass N, Oliveira LG, Mattar R. Cytokine genotyping in preeclampsia. Am J Reprod Immunol. 2006;55(2):130-135.
62. Goddard KA, Tromp G, Romero R, et al. Candidate-gene association study of mothers with pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum Hered. 2007;63(1):1-16.
63. Carter AM, Pijnenborg R. Evolution of invasive placentation with special reference to non-human primates. Best Pract Res Clin Obstet Gynaecol. 2011;25(3):249-257.
64. Kanasaki K, Palmsten K, Sugimoto H, et al. Deficiency in catechol- O-methyltransferase and 2-methoxyoestradiol is associated with pre- eclampsia. Nature. 2008;453(7198):1117-1121.
65. Berg D, Sonsalla R, Kuss E. Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh). 1983;103(2): 282-288.
66. Sata F, Yamada H, Suzuki K, et al. Functional maternal catechol- O-methyltransferase polymorphism and fetal growth restriction. Pharmacogenet Genomics. 2006;16(11):775-781.
67. Arngrimsson R, Sigurardttir S, Frigge ML, et al. A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Hum Mol Genet. 1999;8(9):1799-1805.
68. Laivuori H, Lahermo P, Ollikainen V, et al. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet. 2003;72(1):168-177.
69. Moses EK, Lade JA, Guo G, et al. A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet. 2000;67(6):1581-1585.
70. Lachmeijer AM, Arngrimsson R, Bastiaans EJ, et al. A genome-wide scan for preeclampsia in the Netherlands. Eur J Hum Genet. 2001;9(10): 758-764.
71. Zintzaras E, Kitsios G, Harrison GA, et al. Heterogeneity-based genome search meta-analysis for preeclampsia. Hum Genet. 2006;120(3): 360-370.
72. Akolekar R, Etchegaray A, Zhou Y, Maiz N, Nicolaides KH. Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther. 2009;25(3):320-327.
73. Roten LT, Johnson MP, Forsmo S, et al. Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study). Eur J Hum Genet. 2009;17(2):250-257.
74. Fitzpatrick E, Johnson MP, Dyer TD, et al. Genetic association of the activin A receptor gene (ACVR2A) and pre-eclampsia. Mol Hum Reprod. 2009;15(3):195-204.
75. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4(6):446-456.
76. Kandabashi T, Shimokawa H, Miyata K, et al. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation. 2000;101(11):1319-1323.
77. Ark M, Yilmaz N, Yazici G, Kubat H, Aktas S. Rho-associated protein kinase II (rock II) expression in normal and preeclamptic human placentas. Placenta. 2005;26(1):81-84.
78. Peterson H, Laivuori H, Kerkela E, et al. ROCK2 allelic variants are not associated with pre-eclampsia susceptibility in the Finnish population. Mol Hum Reprod. 2009;15(7):443-449.
79. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661-678.
80. Founds SA, Conley YP, Lyons-Weiler JF, Jeyabalan A, Hogge WA, Conrad KP. Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. Placenta. 2009; 30(1):15-24.
81. National Institute of Clinical Excellence (NICE). Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. NICE Clinical Guideline CG107. London: NICE; 2011. Available from: http://www.nice.org.uk/nicemedia/live/13098/50475/50475.pdf. Accessed January 13, 2012.
82. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15-19.
83. Hughes AR, Spreen WR, Mosteller M, et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to conf irmation to clinical utility. Pharmacogenomics J. 2008;8(6): 365-374.
84. Nelson MR, Bacanu SA, Mosteller M, et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J. 2009;9(1):23-33.
85. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009; 360(8):753-764.
86. Auffray C, Charron D, Hood L. Predictive, preventive, personalized and participatory medicine: back to the future. Genome Med. 2010;2(8):57.
87. PharmGkb [database on the Internet]. Available from: http://www.pharmgkb.org/. Accessed January 6, 2012.
88. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329(27):2002-2012.
89. Dudzinski DM, Michel T, Colman RW, et al. The vascular biology of nitric oxide and nitric oxide synthases. In: Colman RW, Clowes AW, Goldhaber SZ, et al. editors. Hemostasis and Thrombosis: Basic Prinicples and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005:653-666.
90. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997;48:489-509.
91. Sandrim VC, Palei AC, Metzger IF, Gomes VA, Cavalli RC, Tanus- Santos JE. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension. 2008;52(2): 402-407.
92. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986;320(6061):454-456.
93. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A. 1998;95(16):9220-9225.
94. Marsden PA, Heng HH, Scherer SW, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem. 1993;268(23):17478-17488.
95. Miyahara K, Kawamoto T, Sase K, et al. Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene. Eur J Biochem. 1994;223(3):719-726.
96. Sandrim VC, Palei AC, Cavalli RC, et al. Vascular endothelial growth factor genotypes and haplotypes are associated with preeclampsia but not with gestational hypertension. Mol Hum Reprod. 2009;15(2):115-120.
97. Cooke GE, Doshi A, Binkley PF. Endothelial nitric oxide synthase gene: prospects for treatment of heart disease. Pharmacogenomics. 2007;8(12):1723-1734.
98. Pereira TV, Rudnicki M, Cheung BM, et al. Three endothelial nitric oxide (NOS3) gene polymorphisms in hypertensive and normotensive individuals: meta-analysis of 53 studies reveals evidence of publication bias. J Hypertens. 2007;25(9):1763-1774.
99. Silva PS, Lacchini R, Gomes Vde A, Tanus-Santos JE. Pharmacogenetic implications of the eNOS polymorphisms for cardiovascular action drugs. Arq Bras Cardiol. 2011;96(2):e27-e34.
100. Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A. 2011;108(4):1451-1455.
101. Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb Res. 2011;127 Suppl 3:S72-S75.
102. Abe K, Nakayama M, Yoshimura M, et al. Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: a relation with the -786T. C polymorphism > Pharmacogenet Genomics. 2005;15(5):329-336.
103. Nagassaki S, Sertorio JT, Metzger IF, Bem AF, Rocha JB, Tanus- Santos JE. eNOS gene T-786C polymorphism modulates atorvastatininduced increase in blood nitrite. Free Radic Biol Med. 2006;41(7): 1044-1049.
104. Souza-Costa DC, Sandrim VC, Lopes LF, Gerlach RF, Rego EM, Tanus-Santos JE. Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene. Atherosclerosis. 2007;193(2):438-444.
105. Kunnas TA, Lehtimaki T, Laaksonen R, et al. Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study. J Mol Med (Berl). 2002;80(12):802-807.
106. Liljedahl U, Karlsson J, Melhus H, et al. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics. 2003;13(1):7-17.
107. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2006;3:CD001449.
108. Lemke LE, McQueen CA. Acetylation and its role in the mutagenicity of the antihypertensive agent hydralazine. Drug Metab Dispos. 1995;23(5):559-565.
109. Sim E, Lack N, Wang CJ, et al. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology. 2008;254(3):170-183.
110. Barnea ER, Fakih H, Oelsner G, Walner S, DeCherney AH, Naftolin F. Effect of antihypertensive drugs on catechol-O-methyltransferase and monoamine oxidase activity in human term placental explants. Gynecol Obstet Invest. 1986;21(3):124-130.
111. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369(9575):1791-1798.
112. Shimokawa T, Smith WL. Prostaglandin endoperoxide synthase. The aspirin acetylation region. J Biol Chem. 1992;267(17):12387-12392.
113. Shantsila E, Watson T, Lip GY. Aspirin resistance: what, why and when? Thromb Res. 2007;119(5):551-554.
114. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol. 2009;103(Suppl 3):27A-34A.
115. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88(3):230-235.
116. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997;78(3): 1003-1007.
117. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005;46(9):1705-1709.
118. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin- Induced Platelet Effect (ASPECT) study. Circulation. 2007;115(25): 3156-3164.
119. Cambria-Kiely JA, Gandhi PJ. Possible mechanisms of aspirin resistance. J Thromb Thrombolysis. 2002;13(1):49-56.
120. Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol. 2004;43(6):1127-1129.
121. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006;27(6):647-654.
122. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther. 2003;73(1):122-130.
123. Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke. 2005;36(2): 276-280.
124. Goodman T, Sharma P, Ferro A. The genetics of aspirin resistance. Int J Clin Pract. 2007;61(5):826-834.
125. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol. 2008;66(2):222-232.
126. Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation. 2000;101(9):1013-1018.
127. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt- Clermont PJ. PlA2 polymorphism and efficacy of aspirin. Lancet. 1998;351(9111):1253.
128. Corral J, Gonzalez-Conejero R, Rivera J, Ortuno F, Aparicio P, Vicente V. Role of the 807 C/T polymorphism of the alpha2 gene in platelet GP Ia collagen receptor expression and function - effect in thromboembolic diseases. Thromb Haemost. 1999;81(6):951-956.
129. Belfort MA. The effect of magnesium sulphate on blood flow velocity in the maternal retina in mild pre-eclampsia: a preliminary colour flow Doppler study. Br J Obstet Gynaecol. 1992;99(8): 641-645.
130. Sadeh M. Action of magnesium sulfate in the treatment of preeclampsia- eclampsia. Stroke. 1989;20(9):1273-1275.
131. Duley L, Gulmezoglu AM, Henderson-Smart DJ. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev. 2003;2:CD000025.
132. Witlin AG, Friedman SA, Sibai BM. The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 1997;176(3):623-627.
133. Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002;359(9321): 1877-1890.
134. Lipsitz PJ. The clinical and biochemical effects of excess magnesium in the newborn. Pediatrics. 1971;47(3):501-509.
135. Magee LA, Abalos E, von Dadelszen P, Sibai B, Easterling T, Walkinshaw S. How to manage hypertension in pregnancy effectively. Br J Clin Pharmacol. 2011;72(3):394-401.
136. Bremer T, Man A, Kask K, Diamond C. CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. Pharmacogenomics. 2006;7(3):271-279.
137. Beitelshees AL, Navare H, Wang D, et al. CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet. 2009;2(4):362-370.
138. Langaee TY, Gong Y, Yarandi HN, et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther. 2007;81(3):386-391.
139. Beitelshees AL, Gong Y, Wang D, et al. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics. 2007;17(9):719-729.
140. Pacanowski MA, Gong Y, Cooper-Dehoff RM, et al. beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther. 2008;84(6):715-721.
141. Lynch AI, Boerwinkle E, Davis BR, et al. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA. 2008;299(3):296-307.
142. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers' Lives: Reviewing Maternal Deaths to Make Motherhood Safer - 2003-2005. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. Lewis G, editor. London: CEMACH; 2007.